Single Dose Preoperative Gabapentin Use in Minimally Invasive Hysterectomy for Acute Pain Management

• Status: Completed
• Trial end date: 2017-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of the investigators' study is to assess the efficacy of a single dose of preoperative gabapentin within an enhanced recovery after surgery protocol in acute postoperative pain reduction for women undergoing a minimally invasive hysterectomy. Participants who consent to participate will be randomized to either a control group without gabapentin or to a study arm and receive gabapentin 600 mg prior to their planned surgery. The investigators will collect data on postoperative narcotic use, subjective pain as rated by a numeric pain scale, in addition to any adverse effects of single dose gabapentin use.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Christiana Care Health Services
• Treatments: Acetaminophen; Celecoxib; Gabapentin; gamma-Aminobutyric Acid

Criteria

Inclusion Criteria:

• undergoing a minimally invasive hysterectomy with surgeons operating within the Christiana Care Health System at the Newark location only.

• at least 18 years of age

• able to swallow tablets or capsules

Exclusion Criteria:

• liver failure

• renal failure

• prior gastric bypass

• gastroparesis

• recent or current regular gabapentin use

• hypersensitivity to gabapentin, acetominophen, or celecoxib

• procedure is converted to laparotomy for any indication. (Mini-laparotomy for specimen removal alone will not be excluded.)